Drugs / AL-3778
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03032536 | Jan → Jun 2017 | chronic hepatitis B virus infection | Alios Biopharma Inc. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03125213 Comparator | Sep 2017 → Feb 2019 | chronic hepatitis B virus infection | Alios Biopharma Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL-3778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03032536 ↗ |
| Route | Oral | “Relative Oral Bioavailability of AL-3778 Tablets” NCT03032536 ↗ |